Robert W. Baird analyst Brian Skorney maintained a Hold rating on Regeneron (REGN – Research Report) on October 22 and set a price target ...
To request a FREE 2-week trial subscription, please signup. NOTE - this can take up to 48hrs to be approved.
J.P. Morgan analyst Chris Schott maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,150.00.
This webinar explores how immersing yourself in the patient experience can add measurable, actionable value to your approach ...
Amgen's move follows the lifting of a temporary injunction on the launch of its Pavblu-branded biosimilar by the US Court of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback